nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ALB—Estropipate—osteoporosis	0.0648	0.115	CbGbCtD
Gefitinib—CYP1A1—Cholecalciferol—osteoporosis	0.0447	0.0792	CbGbCtD
Gefitinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0445	0.0788	CbGbCtD
Gefitinib—ABCG2—Estradiol—osteoporosis	0.039	0.0692	CbGbCtD
Gefitinib—CYP1A1—Estradiol—osteoporosis	0.036	0.0638	CbGbCtD
Gefitinib—CYP2C9—Estropipate—osteoporosis	0.0349	0.0619	CbGbCtD
Gefitinib—ALB—Estradiol—osteoporosis	0.0269	0.0477	CbGbCtD
Gefitinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0218	0.0387	CbGbCtD
Gefitinib—CYP2C19—Cholecalciferol—osteoporosis	0.0216	0.0383	CbGbCtD
Gefitinib—CYP3A5—Estradiol—osteoporosis	0.0216	0.0383	CbGbCtD
Gefitinib—CYP3A4—Estropipate—osteoporosis	0.0203	0.036	CbGbCtD
Gefitinib—CYP3A4—Calcitriol—osteoporosis	0.0203	0.036	CbGbCtD
Gefitinib—CYP2C9—Cholecalciferol—osteoporosis	0.018	0.0319	CbGbCtD
Gefitinib—CYP2C19—Estradiol—osteoporosis	0.0174	0.0309	CbGbCtD
Gefitinib—CYP2D6—Cholecalciferol—osteoporosis	0.0165	0.0291	CbGbCtD
Gefitinib—CYP3A4—Ergocalciferol—osteoporosis	0.0162	0.0288	CbGbCtD
Gefitinib—ABCB1—Conjugated Estrogens—osteoporosis	0.016	0.0284	CbGbCtD
Gefitinib—CYP2C9—Estradiol—osteoporosis	0.0145	0.0257	CbGbCtD
Gefitinib—ABCB1—Estradiol—osteoporosis	0.0141	0.0249	CbGbCtD
Gefitinib—CYP3A4—Raloxifene—osteoporosis	0.0135	0.024	CbGbCtD
Gefitinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0131	0.0232	CbGbCtD
Gefitinib—CYP3A4—Cholecalciferol—osteoporosis	0.0105	0.0185	CbGbCtD
Gefitinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0096	0.017	CbGbCtD
Gefitinib—CYP3A4—Estradiol—osteoporosis	0.00843	0.0149	CbGbCtD
Gefitinib—MKNK1—Estradiol—Estropipate—osteoporosis	0.00141	0.247	CbGdCrCtD
Gefitinib—MKNK1—Estradiol—Conjugated Estrogens—osteoporosis	0.00107	0.187	CbGdCrCtD
Gefitinib—ORM1—vertebral column—osteoporosis	0.000906	0.222	CbGeAlD
Gefitinib—MKNK1—Estradiol—Ethinyl Estradiol—osteoporosis	0.0009	0.157	CbGdCrCtD
Gefitinib—CHEK2—Fulvestrant—Estradiol—osteoporosis	0.000783	0.137	CbGdCrCtD
Gefitinib—CSNK1E—Danazol—Ethinyl Estradiol—osteoporosis	0.000668	0.116	CbGdCrCtD
Gefitinib—CHEK2—bone marrow—osteoporosis	0.00037	0.0908	CbGeAlD
Gefitinib—CHEK2—Danazol—Ethinyl Estradiol—osteoporosis	0.000342	0.0596	CbGdCrCtD
Gefitinib—Angioedema—Pamidronate—osteoporosis	0.000341	0.0014	CcSEcCtD
Gefitinib—Malnutrition—Zoledronate—osteoporosis	0.000341	0.0014	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00034	0.0014	CcSEcCtD
Gefitinib—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00034	0.0014	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000339	0.00139	CcSEcCtD
Gefitinib—Pneumonia—Estradiol—osteoporosis	0.000338	0.00139	CcSEcCtD
Gefitinib—Decreased appetite—Ibandronate—osteoporosis	0.000338	0.00139	CcSEcCtD
Gefitinib—Arrhythmia—Conjugated Estrogens—osteoporosis	0.000337	0.00139	CcSEcCtD
Gefitinib—Malaise—Pamidronate—osteoporosis	0.000337	0.00138	CcSEcCtD
Gefitinib—Infestation NOS—Estradiol—osteoporosis	0.000336	0.00138	CcSEcCtD
Gefitinib—Infestation—Estradiol—osteoporosis	0.000336	0.00138	CcSEcCtD
Gefitinib—Pain—Raloxifene—osteoporosis	0.000336	0.00138	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000336	0.00138	CcSEcCtD
Gefitinib—Fatigue—Ibandronate—osteoporosis	0.000335	0.00138	CcSEcCtD
Gefitinib—Alopecia—Conjugated Estrogens—osteoporosis	0.000333	0.00137	CcSEcCtD
Gefitinib—Pain—Ibandronate—osteoporosis	0.000332	0.00137	CcSEcCtD
Gefitinib—Constipation—Ibandronate—osteoporosis	0.000332	0.00137	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000332	0.00137	CcSEcCtD
Gefitinib—Pruritus—Etidronic acid—osteoporosis	0.000332	0.00136	CcSEcCtD
Gefitinib—Gastrointestinal pain—Estropipate—osteoporosis	0.000332	0.00136	CcSEcCtD
Gefitinib—Decreased appetite—Calcitriol—osteoporosis	0.000331	0.00136	CcSEcCtD
Gefitinib—Malnutrition—Conjugated Estrogens—osteoporosis	0.000328	0.00135	CcSEcCtD
Gefitinib—Dry mouth—Risedronate—osteoporosis	0.000327	0.00134	CcSEcCtD
Gefitinib—Conjunctivitis—Estradiol—osteoporosis	0.000327	0.00134	CcSEcCtD
Gefitinib—Gastrointestinal pain—Alendronate—osteoporosis	0.000327	0.00134	CcSEcCtD
Gefitinib—Infection—Ethinyl Estradiol—osteoporosis	0.000326	0.00134	CcSEcCtD
Gefitinib—Cough—Pamidronate—osteoporosis	0.000326	0.00134	CcSEcCtD
Gefitinib—Constipation—Calcitriol—osteoporosis	0.000325	0.00134	CcSEcCtD
Gefitinib—Pain—Calcitriol—osteoporosis	0.000325	0.00134	CcSEcCtD
Gefitinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000322	0.00133	CcSEcCtD
Gefitinib—Urticaria—Estropipate—osteoporosis	0.000322	0.00132	CcSEcCtD
Gefitinib—Gastrointestinal pain—Raloxifene—osteoporosis	0.000321	0.00132	CcSEcCtD
Gefitinib—Diarrhoea—Etidronic acid—osteoporosis	0.000321	0.00132	CcSEcCtD
Gefitinib—Haematuria—Estradiol—osteoporosis	0.000321	0.00132	CcSEcCtD
Gefitinib—Abdominal pain—Estropipate—osteoporosis	0.00032	0.00132	CcSEcCtD
Gefitinib—Body temperature increased—Estropipate—osteoporosis	0.00032	0.00132	CcSEcCtD
Gefitinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000319	0.00131	CcSEcCtD
Gefitinib—Infection—Risedronate—osteoporosis	0.000318	0.00131	CcSEcCtD
Gefitinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000318	0.00131	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000318	0.00131	CcSEcCtD
Gefitinib—Urticaria—Alendronate—osteoporosis	0.000317	0.0013	CcSEcCtD
Gefitinib—Epistaxis—Estradiol—osteoporosis	0.000317	0.0013	CcSEcCtD
Gefitinib—Body temperature increased—Alendronate—osteoporosis	0.000316	0.0013	CcSEcCtD
Gefitinib—Abdominal pain—Alendronate—osteoporosis	0.000316	0.0013	CcSEcCtD
Gefitinib—Shock—Risedronate—osteoporosis	0.000315	0.0013	CcSEcCtD
Gefitinib—Anaemia—Zoledronate—osteoporosis	0.000315	0.0013	CcSEcCtD
Gefitinib—Nervous system disorder—Risedronate—osteoporosis	0.000314	0.00129	CcSEcCtD
Gefitinib—Angioedema—Zoledronate—osteoporosis	0.000311	0.00128	CcSEcCtD
Gefitinib—Skin disorder—Risedronate—osteoporosis	0.000311	0.00128	CcSEcCtD
Gefitinib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000311	0.00128	CcSEcCtD
Gefitinib—Abdominal pain—Raloxifene—osteoporosis	0.00031	0.00128	CcSEcCtD
Gefitinib—Body temperature increased—Raloxifene—osteoporosis	0.00031	0.00128	CcSEcCtD
Gefitinib—Urticaria—Ibandronate—osteoporosis	0.000309	0.00127	CcSEcCtD
Gefitinib—CHEK2—Norethindrone—Ethinyl Estradiol—osteoporosis	0.000308	0.0537	CbGdCrCtD
Gefitinib—Malaise—Zoledronate—osteoporosis	0.000307	0.00126	CcSEcCtD
Gefitinib—Abdominal pain—Ibandronate—osteoporosis	0.000307	0.00126	CcSEcCtD
Gefitinib—Body temperature increased—Ibandronate—osteoporosis	0.000307	0.00126	CcSEcCtD
Gefitinib—Haemoglobin—Estradiol—osteoporosis	0.000303	0.00125	CcSEcCtD
Gefitinib—Infection—Pamidronate—osteoporosis	0.000303	0.00124	CcSEcCtD
Gefitinib—Urticaria—Calcitriol—osteoporosis	0.000302	0.00124	CcSEcCtD
Gefitinib—Haemorrhage—Estradiol—osteoporosis	0.000302	0.00124	CcSEcCtD
Gefitinib—Hepatitis—Estradiol—osteoporosis	0.000302	0.00124	CcSEcCtD
Gefitinib—Abdominal pain—Calcitriol—osteoporosis	0.000301	0.00124	CcSEcCtD
Gefitinib—Body temperature increased—Calcitriol—osteoporosis	0.000301	0.00124	CcSEcCtD
Gefitinib—Angioedema—Conjugated Estrogens—osteoporosis	0.0003	0.00123	CcSEcCtD
Gefitinib—Shock—Pamidronate—osteoporosis	0.0003	0.00123	CcSEcCtD
Gefitinib—Hypersensitivity—Estropipate—osteoporosis	0.000299	0.00123	CcSEcCtD
Gefitinib—Nervous system disorder—Pamidronate—osteoporosis	0.000299	0.00123	CcSEcCtD
Gefitinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000298	0.00123	CcSEcCtD
Gefitinib—Urinary tract disorder—Estradiol—osteoporosis	0.000298	0.00123	CcSEcCtD
Gefitinib—Vomiting—Etidronic acid—osteoporosis	0.000298	0.00123	CcSEcCtD
Gefitinib—Cough—Zoledronate—osteoporosis	0.000297	0.00122	CcSEcCtD
Gefitinib—Oedema peripheral—Estradiol—osteoporosis	0.000297	0.00122	CcSEcCtD
Gefitinib—Urethral disorder—Estradiol—osteoporosis	0.000296	0.00122	CcSEcCtD
Gefitinib—Rash—Etidronic acid—osteoporosis	0.000295	0.00122	CcSEcCtD
Gefitinib—Dermatitis—Etidronic acid—osteoporosis	0.000295	0.00121	CcSEcCtD
Gefitinib—Hypersensitivity—Alendronate—osteoporosis	0.000294	0.00121	CcSEcCtD
Gefitinib—Asthenia—Estropipate—osteoporosis	0.000291	0.0012	CcSEcCtD
Gefitinib—Anorexia—Pamidronate—osteoporosis	0.00029	0.00119	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000288	0.00119	CcSEcCtD
Gefitinib—EGFR—uterus—osteoporosis	0.000287	0.0705	CbGeAlD
Gefitinib—Pruritus—Estropipate—osteoporosis	0.000287	0.00118	CcSEcCtD
Gefitinib—Asthenia—Alendronate—osteoporosis	0.000286	0.00118	CcSEcCtD
Gefitinib—Hypersensitivity—Ibandronate—osteoporosis	0.000286	0.00118	CcSEcCtD
Gefitinib—Cough—Conjugated Estrogens—osteoporosis	0.000286	0.00118	CcSEcCtD
Gefitinib—Dyspnoea—Risedronate—osteoporosis	0.000286	0.00117	CcSEcCtD
Gefitinib—Erythema multiforme—Estradiol—osteoporosis	0.000285	0.00117	CcSEcCtD
Gefitinib—Hypotension—Pamidronate—osteoporosis	0.000285	0.00117	CcSEcCtD
Gefitinib—Dry mouth—Zoledronate—osteoporosis	0.000284	0.00117	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000284	0.00117	CcSEcCtD
Gefitinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000283	0.00117	CcSEcCtD
Gefitinib—Pruritus—Alendronate—osteoporosis	0.000283	0.00116	CcSEcCtD
Gefitinib—Eye disorder—Estradiol—osteoporosis	0.000282	0.00116	CcSEcCtD
Gefitinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000281	0.00116	CcSEcCtD
Gefitinib—Hypersensitivity—Calcitriol—osteoporosis	0.00028	0.00115	CcSEcCtD
Gefitinib—Cardiac disorder—Estradiol—osteoporosis	0.00028	0.00115	CcSEcCtD
Gefitinib—Asthenia—Ibandronate—osteoporosis	0.000279	0.00115	CcSEcCtD
Gefitinib—Nausea—Etidronic acid—osteoporosis	0.000278	0.00114	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000278	0.00114	CcSEcCtD
Gefitinib—Diarrhoea—Estropipate—osteoporosis	0.000277	0.00114	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000277	0.00114	CcSEcCtD
Gefitinib—CSNK1E—uterus—osteoporosis	0.000276	0.0678	CbGeAlD
Gefitinib—Infection—Zoledronate—osteoporosis	0.000276	0.00114	CcSEcCtD
Gefitinib—Fatigue—Risedronate—osteoporosis	0.000276	0.00114	CcSEcCtD
Gefitinib—Pruritus—Ibandronate—osteoporosis	0.000275	0.00113	CcSEcCtD
Gefitinib—Constipation—Risedronate—osteoporosis	0.000274	0.00113	CcSEcCtD
Gefitinib—Pain—Risedronate—osteoporosis	0.000274	0.00113	CcSEcCtD
Gefitinib—Angiopathy—Estradiol—osteoporosis	0.000274	0.00113	CcSEcCtD
Gefitinib—Shock—Zoledronate—osteoporosis	0.000274	0.00113	CcSEcCtD
Gefitinib—Diarrhoea—Alendronate—osteoporosis	0.000273	0.00112	CcSEcCtD
Gefitinib—Asthenia—Calcitriol—osteoporosis	0.000273	0.00112	CcSEcCtD
Gefitinib—Nervous system disorder—Zoledronate—osteoporosis	0.000273	0.00112	CcSEcCtD
Gefitinib—Thrombocytopenia—Zoledronate—osteoporosis	0.000272	0.00112	CcSEcCtD
Gefitinib—Mediastinal disorder—Estradiol—osteoporosis	0.000272	0.00112	CcSEcCtD
Gefitinib—Dyspnoea—Pamidronate—osteoporosis	0.000272	0.00112	CcSEcCtD
Gefitinib—Skin disorder—Zoledronate—osteoporosis	0.00027	0.00111	CcSEcCtD
Gefitinib—Pruritus—Calcitriol—osteoporosis	0.000269	0.00111	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000269	0.00111	CcSEcCtD
Gefitinib—Diarrhoea—Raloxifene—osteoporosis	0.000269	0.00111	CcSEcCtD
Gefitinib—ERBB3—uterus—osteoporosis	0.000267	0.0654	CbGeAlD
Gefitinib—Alopecia—Estradiol—osteoporosis	0.000267	0.0011	CcSEcCtD
Gefitinib—Infection—Conjugated Estrogens—osteoporosis	0.000266	0.00109	CcSEcCtD
Gefitinib—Diarrhoea—Ibandronate—osteoporosis	0.000266	0.00109	CcSEcCtD
Gefitinib—Anorexia—Zoledronate—osteoporosis	0.000265	0.00109	CcSEcCtD
Gefitinib—Decreased appetite—Pamidronate—osteoporosis	0.000265	0.00109	CcSEcCtD
Gefitinib—Shock—Conjugated Estrogens—osteoporosis	0.000264	0.00108	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000263	0.00108	CcSEcCtD
Gefitinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000263	0.00108	CcSEcCtD
Gefitinib—Malnutrition—Estradiol—osteoporosis	0.000263	0.00108	CcSEcCtD
Gefitinib—Fatigue—Pamidronate—osteoporosis	0.000263	0.00108	CcSEcCtD
Gefitinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000262	0.00108	CcSEcCtD
Gefitinib—Urticaria—Ethinyl Estradiol—osteoporosis	0.000261	0.00107	CcSEcCtD
Gefitinib—Constipation—Pamidronate—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Pain—Pamidronate—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Diarrhoea—Calcitriol—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Hypotension—Zoledronate—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00026	0.00107	CcSEcCtD
Gefitinib—Vomiting—Estropipate—osteoporosis	0.000258	0.00106	CcSEcCtD
Gefitinib—Rash—Estropipate—osteoporosis	0.000256	0.00105	CcSEcCtD
Gefitinib—Dermatitis—Estropipate—osteoporosis	0.000255	0.00105	CcSEcCtD
Gefitinib—Anorexia—Conjugated Estrogens—osteoporosis	0.000255	0.00105	CcSEcCtD
Gefitinib—Urticaria—Risedronate—osteoporosis	0.000255	0.00105	CcSEcCtD
Gefitinib—Vomiting—Alendronate—osteoporosis	0.000254	0.00104	CcSEcCtD
Gefitinib—MKNK2—uterus—osteoporosis	0.000254	0.0622	CbGeAlD
Gefitinib—Abdominal pain—Risedronate—osteoporosis	0.000253	0.00104	CcSEcCtD
Gefitinib—Body temperature increased—Risedronate—osteoporosis	0.000253	0.00104	CcSEcCtD
Gefitinib—Rash—Alendronate—osteoporosis	0.000252	0.00104	CcSEcCtD
Gefitinib—Dermatitis—Alendronate—osteoporosis	0.000252	0.00103	CcSEcCtD
Gefitinib—Hypotension—Conjugated Estrogens—osteoporosis	0.00025	0.00103	CcSEcCtD
Gefitinib—Vomiting—Raloxifene—osteoporosis	0.00025	0.00103	CcSEcCtD
Gefitinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000249	0.00102	CcSEcCtD
Gefitinib—Dyspnoea—Zoledronate—osteoporosis	0.000248	0.00102	CcSEcCtD
Gefitinib—Rash—Raloxifene—osteoporosis	0.000248	0.00102	CcSEcCtD
Gefitinib—Dermatitis—Raloxifene—osteoporosis	0.000247	0.00102	CcSEcCtD
Gefitinib—Vomiting—Ibandronate—osteoporosis	0.000247	0.00102	CcSEcCtD
Gefitinib—Rash—Ibandronate—osteoporosis	0.000245	0.00101	CcSEcCtD
Gefitinib—CHEK2—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000245	0.0428	CbGdCrCtD
Gefitinib—Dermatitis—Ibandronate—osteoporosis	0.000245	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000242	0.000996	CcSEcCtD
Gefitinib—Vomiting—Calcitriol—osteoporosis	0.000242	0.000995	CcSEcCtD
Gefitinib—Decreased appetite—Zoledronate—osteoporosis	0.000242	0.000995	CcSEcCtD
Gefitinib—Nausea—Estropipate—osteoporosis	0.000241	0.00099	CcSEcCtD
Gefitinib—Body temperature increased—Pamidronate—osteoporosis	0.000241	0.00099	CcSEcCtD
Gefitinib—Abdominal pain—Pamidronate—osteoporosis	0.000241	0.00099	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00024	0.000988	CcSEcCtD
Gefitinib—Angioedema—Estradiol—osteoporosis	0.00024	0.000987	CcSEcCtD
Gefitinib—Rash—Calcitriol—osteoporosis	0.00024	0.000987	CcSEcCtD
Gefitinib—Fatigue—Zoledronate—osteoporosis	0.00024	0.000987	CcSEcCtD
Gefitinib—Dermatitis—Calcitriol—osteoporosis	0.00024	0.000986	CcSEcCtD
Gefitinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000239	0.000982	CcSEcCtD
Gefitinib—Constipation—Zoledronate—osteoporosis	0.000238	0.000979	CcSEcCtD
Gefitinib—Pain—Zoledronate—osteoporosis	0.000238	0.000979	CcSEcCtD
Gefitinib—Nausea—Alendronate—osteoporosis	0.000237	0.000976	CcSEcCtD
Gefitinib—Malaise—Estradiol—osteoporosis	0.000237	0.000974	CcSEcCtD
Gefitinib—Hypersensitivity—Risedronate—osteoporosis	0.000236	0.000971	CcSEcCtD
Gefitinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000236	0.00097	CcSEcCtD
Gefitinib—Nausea—Raloxifene—osteoporosis	0.000233	0.000959	CcSEcCtD
Gefitinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000233	0.000958	CcSEcCtD
Gefitinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000232	0.000956	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000231	0.000951	CcSEcCtD
Gefitinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000231	0.00095	CcSEcCtD
Gefitinib—IRAK4—bone marrow—osteoporosis	0.000231	0.0567	CbGeAlD
Gefitinib—Nausea—Ibandronate—osteoporosis	0.000231	0.00095	CcSEcCtD
Gefitinib—Asthenia—Risedronate—osteoporosis	0.00023	0.000945	CcSEcCtD
Gefitinib—Cough—Estradiol—osteoporosis	0.000229	0.000943	CcSEcCtD
Gefitinib—Pain—Conjugated Estrogens—osteoporosis	0.000229	0.000942	CcSEcCtD
Gefitinib—Constipation—Conjugated Estrogens—osteoporosis	0.000229	0.000942	CcSEcCtD
Gefitinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000227	0.000936	CcSEcCtD
Gefitinib—Pruritus—Risedronate—osteoporosis	0.000227	0.000932	CcSEcCtD
Gefitinib—Nausea—Calcitriol—osteoporosis	0.000226	0.00093	CcSEcCtD
Gefitinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000225	0.000925	CcSEcCtD
Gefitinib—Hypersensitivity—Pamidronate—osteoporosis	0.000224	0.000923	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000222	0.000914	CcSEcCtD
Gefitinib—Urticaria—Zoledronate—osteoporosis	0.000221	0.000909	CcSEcCtD
Gefitinib—Abdominal pain—Zoledronate—osteoporosis	0.00022	0.000905	CcSEcCtD
Gefitinib—Body temperature increased—Zoledronate—osteoporosis	0.00022	0.000905	CcSEcCtD
Gefitinib—Diarrhoea—Risedronate—osteoporosis	0.000219	0.000902	CcSEcCtD
Gefitinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000219	0.000901	CcSEcCtD
Gefitinib—Dry mouth—Estradiol—osteoporosis	0.000219	0.0009	CcSEcCtD
Gefitinib—Asthenia—Pamidronate—osteoporosis	0.000219	0.000899	CcSEcCtD
Gefitinib—Pruritus—Pamidronate—osteoporosis	0.000215	0.000886	CcSEcCtD
Gefitinib—MKNK2—bone marrow—osteoporosis	0.000215	0.0528	CbGeAlD
Gefitinib—IRAK1—bone marrow—osteoporosis	0.000215	0.0528	CbGeAlD
Gefitinib—Infection—Estradiol—osteoporosis	0.000213	0.000876	CcSEcCtD
Gefitinib—Urticaria—Conjugated Estrogens—osteoporosis	0.000213	0.000875	CcSEcCtD
Gefitinib—MKNK1—bone marrow—osteoporosis	0.000213	0.0522	CbGeAlD
Gefitinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000212	0.000871	CcSEcCtD
Gefitinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000212	0.000871	CcSEcCtD
Gefitinib—Shock—Estradiol—osteoporosis	0.000211	0.000868	CcSEcCtD
Gefitinib—Nervous system disorder—Estradiol—osteoporosis	0.00021	0.000865	CcSEcCtD
Gefitinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000209	0.000859	CcSEcCtD
Gefitinib—Diarrhoea—Pamidronate—osteoporosis	0.000208	0.000857	CcSEcCtD
Gefitinib—Skin disorder—Estradiol—osteoporosis	0.000208	0.000857	CcSEcCtD
Gefitinib—Rash—Ethinyl Estradiol—osteoporosis	0.000207	0.000852	CcSEcCtD
Gefitinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000207	0.000851	CcSEcCtD
Gefitinib—STK10—uterus—osteoporosis	0.000206	0.0506	CbGeAlD
Gefitinib—Hypersensitivity—Zoledronate—osteoporosis	0.000205	0.000843	CcSEcCtD
Gefitinib—Vomiting—Risedronate—osteoporosis	0.000204	0.000838	CcSEcCtD
Gefitinib—Rash—Risedronate—osteoporosis	0.000202	0.000831	CcSEcCtD
Gefitinib—Dermatitis—Risedronate—osteoporosis	0.000202	0.00083	CcSEcCtD
Gefitinib—Asthenia—Zoledronate—osteoporosis	0.0002	0.000821	CcSEcCtD
Gefitinib—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000197	0.000812	CcSEcCtD
Gefitinib—Pruritus—Zoledronate—osteoporosis	0.000197	0.00081	CcSEcCtD
Gefitinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000195	0.000803	CcSEcCtD
Gefitinib—Vomiting—Pamidronate—osteoporosis	0.000194	0.000796	CcSEcCtD
Gefitinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000192	0.000791	CcSEcCtD
Gefitinib—Rash—Pamidronate—osteoporosis	0.000192	0.00079	CcSEcCtD
Gefitinib—Dermatitis—Pamidronate—osteoporosis	0.000192	0.000789	CcSEcCtD
Gefitinib—Dyspnoea—Estradiol—osteoporosis	0.000191	0.000786	CcSEcCtD
Gefitinib—Diarrhoea—Zoledronate—osteoporosis	0.00019	0.000783	CcSEcCtD
Gefitinib—Nausea—Risedronate—osteoporosis	0.00019	0.000783	CcSEcCtD
Gefitinib—Pruritus—Conjugated Estrogens—osteoporosis	0.00019	0.00078	CcSEcCtD
Gefitinib—Decreased appetite—Estradiol—osteoporosis	0.000186	0.000767	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000185	0.000761	CcSEcCtD
Gefitinib—Fatigue—Estradiol—osteoporosis	0.000185	0.00076	CcSEcCtD
Gefitinib—Constipation—Estradiol—osteoporosis	0.000183	0.000754	CcSEcCtD
Gefitinib—Pain—Estradiol—osteoporosis	0.000183	0.000754	CcSEcCtD
Gefitinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000183	0.000754	CcSEcCtD
Gefitinib—Nausea—Pamidronate—osteoporosis	0.000181	0.000744	CcSEcCtD
Gefitinib—Vomiting—Zoledronate—osteoporosis	0.000177	0.000728	CcSEcCtD
Gefitinib—Rash—Zoledronate—osteoporosis	0.000175	0.000721	CcSEcCtD
Gefitinib—Gastrointestinal pain—Estradiol—osteoporosis	0.000175	0.000721	CcSEcCtD
Gefitinib—Dermatitis—Zoledronate—osteoporosis	0.000175	0.000721	CcSEcCtD
Gefitinib—STK10—bone marrow—osteoporosis	0.000175	0.0429	CbGeAlD
Gefitinib—Vomiting—Conjugated Estrogens—osteoporosis	0.00017	0.000701	CcSEcCtD
Gefitinib—Urticaria—Estradiol—osteoporosis	0.00017	0.000701	CcSEcCtD
Gefitinib—Abdominal pain—Estradiol—osteoporosis	0.000169	0.000697	CcSEcCtD
Gefitinib—Body temperature increased—Estradiol—osteoporosis	0.000169	0.000697	CcSEcCtD
Gefitinib—Rash—Conjugated Estrogens—osteoporosis	0.000169	0.000695	CcSEcCtD
Gefitinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000169	0.000694	CcSEcCtD
Gefitinib—Nausea—Zoledronate—osteoporosis	0.000165	0.00068	CcSEcCtD
Gefitinib—Nausea—Conjugated Estrogens—osteoporosis	0.000159	0.000654	CcSEcCtD
Gefitinib—Hypersensitivity—Estradiol—osteoporosis	0.000158	0.00065	CcSEcCtD
Gefitinib—Asthenia—Estradiol—osteoporosis	0.000154	0.000633	CcSEcCtD
Gefitinib—Pruritus—Estradiol—osteoporosis	0.000152	0.000624	CcSEcCtD
Gefitinib—Diarrhoea—Estradiol—osteoporosis	0.000147	0.000603	CcSEcCtD
Gefitinib—Vomiting—Estradiol—osteoporosis	0.000136	0.000561	CcSEcCtD
Gefitinib—Rash—Estradiol—osteoporosis	0.000135	0.000556	CcSEcCtD
Gefitinib—Dermatitis—Estradiol—osteoporosis	0.000135	0.000555	CcSEcCtD
Gefitinib—Nausea—Estradiol—osteoporosis	0.000127	0.000524	CcSEcCtD
Gefitinib—ORM1—bone marrow—osteoporosis	0.000127	0.0311	CbGeAlD
Gefitinib—ABCG2—uterus—osteoporosis	8.96e-05	0.022	CbGeAlD
Gefitinib—CYP1A1—uterus—osteoporosis	8.51e-05	0.0209	CbGeAlD
Gefitinib—ABCG2—bone marrow—osteoporosis	7.6e-05	0.0187	CbGeAlD
Gefitinib—ABCB1—uterus—osteoporosis	4.42e-05	0.0108	CbGeAlD
Gefitinib—ABCB1—bone marrow—osteoporosis	3.75e-05	0.0092	CbGeAlD
Gefitinib—EGFR—Signaling by GPCR—ADCY5—osteoporosis	1.76e-05	9.66e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6R—osteoporosis	1.76e-05	9.65e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.76e-05	9.65e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—OXCT1—osteoporosis	1.76e-05	9.62e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CA2—osteoporosis	1.76e-05	9.62e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TPI1—osteoporosis	1.76e-05	9.61e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PSMA2—osteoporosis	1.76e-05	9.61e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PSMA5—osteoporosis	1.76e-05	9.61e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IGF1—osteoporosis	1.74e-05	9.51e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6R—osteoporosis	1.73e-05	9.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MGLL—osteoporosis	1.73e-05	9.46e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MGLL—osteoporosis	1.71e-05	9.37e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IRS2—osteoporosis	1.7e-05	9.3e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP27A1—osteoporosis	1.67e-05	9.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—POMC—osteoporosis	1.67e-05	9.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BMP2—osteoporosis	1.66e-05	9.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTHLH—osteoporosis	1.66e-05	9.11e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—LEP—osteoporosis	1.66e-05	9.1e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TPI1—osteoporosis	1.66e-05	9.08e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—P4HB—osteoporosis	1.65e-05	9.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IRS2—osteoporosis	1.64e-05	8.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGB—osteoporosis	1.63e-05	8.91e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ACP5—osteoporosis	1.63e-05	8.91e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GAPDH—osteoporosis	1.62e-05	8.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AGER—osteoporosis	1.62e-05	8.85e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.61e-05	8.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ADCY5—osteoporosis	1.61e-05	8.82e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.61e-05	8.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—LEP—osteoporosis	1.6e-05	8.77e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—IDH2—osteoporosis	1.6e-05	8.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—osteoporosis	1.59e-05	8.7e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ESR1—osteoporosis	1.59e-05	8.69e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1B—osteoporosis	1.58e-05	8.65e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—RAP1A—osteoporosis	1.58e-05	8.64e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PKM—osteoporosis	1.57e-05	8.61e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FDPS—osteoporosis	1.57e-05	8.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PSMA5—osteoporosis	1.57e-05	8.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PSMA2—osteoporosis	1.57e-05	8.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—P4HB—osteoporosis	1.56e-05	8.54e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—IDH2—osteoporosis	1.56e-05	8.53e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ADCY5—osteoporosis	1.56e-05	8.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—osteoporosis	1.55e-05	8.49e-05	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.53e-05	8.39e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GAPDH—osteoporosis	1.53e-05	8.38e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ESR1—osteoporosis	1.53e-05	8.38e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TPI1—osteoporosis	1.51e-05	8.28e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SPP1—osteoporosis	1.51e-05	8.25e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP27A1—osteoporosis	1.5e-05	8.22e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MYC—osteoporosis	1.49e-05	8.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—RAP1A—osteoporosis	1.49e-05	8.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PGLS—osteoporosis	1.49e-05	8.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPD2—osteoporosis	1.49e-05	8.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ADCY5—osteoporosis	1.49e-05	8.15e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TGFB1—osteoporosis	1.49e-05	8.14e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IRS1—osteoporosis	1.48e-05	8.12e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—IDH2—osteoporosis	1.47e-05	8.04e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP27A1—osteoporosis	1.47e-05	8.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CALCA—osteoporosis	1.47e-05	8.02e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ACP5—osteoporosis	1.46e-05	8e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	1.46e-05	7.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—IDH2—osteoporosis	1.46e-05	7.97e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.44e-05	7.89e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—osteoporosis	1.44e-05	7.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.44e-05	7.87e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.43e-05	7.85e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IRS1—osteoporosis	1.43e-05	7.83e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—POMC—osteoporosis	1.43e-05	7.82e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ACP5—osteoporosis	1.43e-05	7.8e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP19A1—osteoporosis	1.42e-05	7.79e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—P4HB—osteoporosis	1.42e-05	7.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRS2—osteoporosis	1.41e-05	7.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—osteoporosis	1.4e-05	7.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GAPDH—osteoporosis	1.4e-05	7.64e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6R—osteoporosis	1.39e-05	7.63e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.38e-05	7.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—POMC—osteoporosis	1.38e-05	7.54e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IGF1—osteoporosis	1.37e-05	7.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.37e-05	7.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTHFR—osteoporosis	1.37e-05	7.49e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IRS2—osteoporosis	1.36e-05	7.46e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PNP—osteoporosis	1.36e-05	7.46e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ATIC—osteoporosis	1.36e-05	7.46e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—RAP1A—osteoporosis	1.36e-05	7.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TPI1—osteoporosis	1.36e-05	7.43e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ACP5—osteoporosis	1.34e-05	7.35e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MYC—osteoporosis	1.34e-05	7.35e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6R—osteoporosis	1.34e-05	7.35e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.34e-05	7.35e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFB1—osteoporosis	1.34e-05	7.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.34e-05	7.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—LEP—osteoporosis	1.33e-05	7.3e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ACP5—osteoporosis	1.33e-05	7.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KL—osteoporosis	1.33e-05	7.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TGFB1—osteoporosis	1.33e-05	7.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TPI1—osteoporosis	1.33e-05	7.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IGF1—osteoporosis	1.32e-05	7.25e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—osteoporosis	1.32e-05	7.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1B—osteoporosis	1.32e-05	7.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.31e-05	7.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IRS2—osteoporosis	1.3e-05	7.13e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.3e-05	7.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—POMC—osteoporosis	1.3e-05	7.1e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—P4HB—osteoporosis	1.28e-05	6.99e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO1—osteoporosis	1.28e-05	6.99e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ESR1—osteoporosis	1.27e-05	6.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6R—osteoporosis	1.27e-05	6.93e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PSMA5—osteoporosis	1.26e-05	6.88e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PSMA2—osteoporosis	1.26e-05	6.88e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GAPDH—osteoporosis	1.25e-05	6.86e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IGF1—osteoporosis	1.25e-05	6.86e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TPI1—osteoporosis	1.25e-05	6.84e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—P4HB—osteoporosis	1.25e-05	6.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—osteoporosis	1.24e-05	6.79e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TPI1—osteoporosis	1.24e-05	6.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRS1—osteoporosis	1.23e-05	6.74e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GAPDH—osteoporosis	1.22e-05	6.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—RAP1A—osteoporosis	1.22e-05	6.68e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO1—osteoporosis	1.21e-05	6.6e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RAP1A—osteoporosis	1.19e-05	6.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IRS1—osteoporosis	1.19e-05	6.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PSMA5—osteoporosis	1.19e-05	6.5e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PSMA2—osteoporosis	1.19e-05	6.5e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.19e-05	6.49e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—P4HB—osteoporosis	1.17e-05	6.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—P4HB—osteoporosis	1.16e-05	6.37e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ADCY5—osteoporosis	1.16e-05	6.37e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—osteoporosis	1.16e-05	6.35e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GPX1—osteoporosis	1.16e-05	6.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—OXCT1—osteoporosis	1.16e-05	6.34e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CA2—osteoporosis	1.16e-05	6.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6R—osteoporosis	1.16e-05	6.33e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GAPDH—osteoporosis	1.15e-05	6.31e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—POMC—osteoporosis	1.15e-05	6.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GAPDH—osteoporosis	1.14e-05	6.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IRS1—osteoporosis	1.14e-05	6.22e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—osteoporosis	1.14e-05	6.22e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—osteoporosis	1.13e-05	6.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MGLL—osteoporosis	1.13e-05	6.18e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RAP1A—osteoporosis	1.12e-05	6.14e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—osteoporosis	1.12e-05	6.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6R—osteoporosis	1.12e-05	6.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RAP1A—osteoporosis	1.11e-05	6.09e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF1—osteoporosis	1.1e-05	6.04e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO1—osteoporosis	1.1e-05	6.02e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PSMA5—osteoporosis	1.08e-05	5.93e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PSMA2—osteoporosis	1.08e-05	5.93e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—osteoporosis	1.07e-05	5.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6R—osteoporosis	1.07e-05	5.84e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.06e-05	5.83e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—osteoporosis	1.04e-05	5.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ADCY5—osteoporosis	1.04e-05	5.7e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—osteoporosis	1.04e-05	5.7e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.02e-05	5.58e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—osteoporosis	1.01e-05	5.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SPP1—osteoporosis	1.01e-05	5.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—osteoporosis	1e-05	5.48e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO1—osteoporosis	9.87e-06	5.4e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PSMA5—osteoporosis	9.72e-06	5.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PSMA2—osteoporosis	9.72e-06	5.32e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.71e-06	5.31e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP19A1—osteoporosis	9.64e-06	5.28e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO1—osteoporosis	9.63e-06	5.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—IDH2—osteoporosis	9.6e-06	5.26e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PSMA5—osteoporosis	9.49e-06	5.19e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PSMA2—osteoporosis	9.49e-06	5.19e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—osteoporosis	9.25e-06	5.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IRS2—osteoporosis	9.12e-06	4.99e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO1—osteoporosis	9.07e-06	4.97e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	9.03e-06	4.94e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO1—osteoporosis	9e-06	4.92e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PSMA5—osteoporosis	8.94e-06	4.89e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PSMA2—osteoporosis	8.94e-06	4.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—LEP—osteoporosis	8.92e-06	4.88e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PSMA2—osteoporosis	8.86e-06	4.85e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PSMA5—osteoporosis	8.86e-06	4.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—osteoporosis	8.84e-06	4.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—osteoporosis	8.8e-06	4.82e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP19A1—osteoporosis	8.79e-06	4.81e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ACP5—osteoporosis	8.78e-06	4.81e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—POMC—osteoporosis	8.56e-06	4.68e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—osteoporosis	8.54e-06	4.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ESR1—osteoporosis	8.52e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ADCY5—osteoporosis	8.34e-06	4.56e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—osteoporosis	8.31e-06	4.55e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—osteoporosis	8.26e-06	4.52e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	8.24e-06	4.51e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TPI1—osteoporosis	8.17e-06	4.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IRS1—osteoporosis	7.96e-06	4.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—osteoporosis	7.96e-06	4.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—osteoporosis	7.94e-06	4.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP19A1—osteoporosis	7.89e-06	4.32e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ADCY5—osteoporosis	7.88e-06	4.31e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—osteoporosis	7.85e-06	4.3e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—osteoporosis	7.85e-06	4.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—osteoporosis	7.7e-06	4.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP19A1—osteoporosis	7.7e-06	4.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—P4HB—osteoporosis	7.68e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—osteoporosis	7.67e-06	4.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—POMC—osteoporosis	7.67e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GAPDH—osteoporosis	7.54e-06	4.12e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—osteoporosis	7.51e-06	4.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6R—osteoporosis	7.48e-06	4.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—osteoporosis	7.37e-06	4.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RAP1A—osteoporosis	7.34e-06	4.02e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP19A1—osteoporosis	7.25e-06	3.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—osteoporosis	7.24e-06	3.96e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP19A1—osteoporosis	7.19e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ADCY5—osteoporosis	7.18e-06	3.93e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—osteoporosis	7.15e-06	3.92e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—osteoporosis	6.63e-06	3.63e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—osteoporosis	6.61e-06	3.62e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—osteoporosis	6.6e-06	3.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ADCY5—osteoporosis	6.44e-06	3.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—osteoporosis	6.42e-06	3.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—osteoporosis	6.33e-06	3.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—osteoporosis	6.31e-06	3.45e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ADCY5—osteoporosis	6.29e-06	3.44e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—osteoporosis	6.27e-06	3.43e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—osteoporosis	6.21e-06	3.4e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—osteoporosis	6.13e-06	3.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—osteoporosis	5.98e-06	3.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO1—osteoporosis	5.93e-06	3.25e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ADCY5—osteoporosis	5.93e-06	3.24e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—osteoporosis	5.93e-06	3.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—osteoporosis	5.91e-06	3.23e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ADCY5—osteoporosis	5.88e-06	3.22e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—osteoporosis	5.86e-06	3.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSMA5—osteoporosis	5.85e-06	3.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSMA2—osteoporosis	5.85e-06	3.2e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—osteoporosis	5.79e-06	3.17e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—osteoporosis	5.79e-06	3.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—osteoporosis	5.64e-06	3.09e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—osteoporosis	5.45e-06	2.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—osteoporosis	5.4e-06	2.96e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—osteoporosis	5.28e-06	2.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—osteoporosis	5.15e-06	2.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—osteoporosis	4.98e-06	2.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—osteoporosis	4.76e-06	2.6e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.74e-06	2.6e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—osteoporosis	4.74e-06	2.59e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—osteoporosis	4.63e-06	2.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—osteoporosis	4.43e-06	2.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—osteoporosis	4.42e-06	2.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—osteoporosis	4.36e-06	2.39e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—osteoporosis	4.32e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADCY5—osteoporosis	3.88e-06	2.12e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—osteoporosis	3.86e-06	2.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—osteoporosis	3.56e-06	1.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—osteoporosis	3.33e-06	1.82e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—osteoporosis	2.85e-06	1.56e-05	CbGpPWpGaD
